Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 11.51
-0.49 (-4.08%)
Sep 25, 2026, 2:12 PM GMT
Fusion Antibodies Market Cap
Fusion Antibodies has a market cap or net worth of 15.02 million as of September 25, 2026. Its market cap has decreased by -29.52% in one year.
Market Cap
15.02M
Enterprise Value
14.31M
Revenue
2.11M
Ranking
n/a
PE Ratio
n/a
Stock Price
11.51
ChartMarket Cap Chart
Since December 18, 2017, Fusion Antibodies's market cap has decreased from 27.28M to 15.02M, a decrease of -44.95%. That is a compound annual growth rate of -6.58%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 24, 2026 | 15.02M | -5.61% |
| Dec 31, 2025 | 15.91M | 135.22% |
| Dec 31, 2024 | 6.76M | 167.72% |
| Dec 29, 2023 | 2.53M | -78.42% |
| Dec 30, 2022 | 11.71M | -59.09% |
| Dec 31, 2021 | 28.62M | -9.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 18, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| ImmuPharma | 24.89M |
| IXICO | 16.20M |
| Oxford BioDynamics | 15.46M |
| SkinBioTherapeutics | 14.90M |
| Palatin Technologies | 13.42M |
| Aptamer Group | 11.23M |
| Genflow Biosciences | 10.62M |
| Solvonis Therapeutics | 7.83M |